However, the GSK-3β/p53 onco-suppressive effect loses its importance in many cancers including pancreatic cancer, where up to 76% of PDAC patients have a p53 mutation inducing its loss of function [36]. This evidence concerns the gene GSK3B and familial pancreatic carcinoma.